Share
Two clinical trials have shown positive topline data that add to the growing body of evidence supporting the efficacy and safety of teprotumumab-trbw for the treatment of Thyroid Eye Disease (TED). Horizon Therapeutics is marketing the drug as TEPEZZA, the first medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of...
Share
Study reports the first known case of subacute thyroiditis after COVID-19 infection COVID-19 infection may cause subacute thyroiditis, according to a new case study published in The Journal of Clinical Endocrinology & Metabolism. Subacute thyroiditis is an inflammatory thyroid disease characterized by neck pain and is usually preceded by an upper respiratory tract infection. It may be caused by a viral infection or a post-viral inflammatory reaction, and many...
Share
[Editor’s Note: A version of this feature appeared in the March issue, prior to the spread of COVID-19 forcing the cancellation of ENDO 2020 in San Francisco.] By and large, endocrinologists treating thyroid nodules seem to be adopting two general principles: Avoid overtreating and include the patient in deciding next steps. Another common theme among...
Share
In January, Endocrine News reported on the possible upcoming availability of teprotumumab as a promising treatment for of thyroid eye disease (TED), a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation, and facial disfigurement. Up to 50% of patients with Graves’ disease...
Share
Endocrine News gets the patient and physician perspective on thyroid eye disease. Patients discuss how it has affected their lives and clinicians explain the limited treatment choices. However, new options may be available soon. Christine Gustafson, of Monterey, Calif., swam a mile a day and biked everywhere she went. When she noticed her heart was...
